Home › Kanser sa Suso › Texas › San Antonio
Pag-aaral pangklinika para sa Kanser sa Suso sa San Antonio, TX
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Antonio. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Research Site, San Antonio
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Audie L Murphy VA Hospital, San Antonio
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Nagre-recruitPhase 2
- UT Health San Antonio, Mays Cancer Center, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- University of Texas San Antonio (UTSA), San Antonio
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Oncology - PARENT, San Antonio
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1
- Next Oncology, San Antonio
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Nagre-recruitPhase 3
- Mays Cancer Center ( Site 0049), San Antonio
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Nagre-recruitPhase 3
- Texas Oncology - San Antonio ( Site 8002), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Nagre-recruitPhase 3
- Clinical Trial Site, San Antonio
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- Texas Oncology - San Antonio Medical Center, San Antonio
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Nagre-recruitPhase 1
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Nagre-recruitPhase 1/2
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- START Center for Cancer Research, San Antonio
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Nagre-recruitPhase 3
- Mays Cancer Center, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Oncology, San Antonio
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Nagre-recruitPhase 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Nagre-recruitPhase 3
- Texas Oncology-San Antonio Cancer Care, San Antonio
- Texas Oncology - San Antonio Northeast, San Antonio
- Texas Oncology - San Antonio Stone Oak, San Antonio
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- University of Texas Health Science Center at San Antonio, San Antonio
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Nagre-recruitPhase 2
- University of Texas Health Science Center at San Antonio, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nagre-recruitPhase 1
- START San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Nagre-recruitPhase 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Nagre-recruitPhase 3
- The University of Texas Health Sciences Center at San Antonio - Mays Cancer Center, San Antonio
- Texas Oncology - San Antonio Medical Center, San Antonio
IDOV-Immune for Advanced Solid Tumors
Nagre-recruitPhase 1
- South Texas Accelerated Research Therapeutics, San Antonio
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1/2
- START, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT San Antonio, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- START San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- START San Antonio, San Antonio
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Nagre-recruitPhase 1/2
- START San Antonio, San Antonio
- Texas Oncology - San Aantonio, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- START, San Antonio
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Nagre-recruitPhase 1
- The University of Texas Health Science Center at San Antonio, San Antonio
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Nagre-recruitPhase 3
- Mays Cancer Center, San Antonio
Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer
Nagre-recruit
- Mays Cancer Center, UT Health San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology, San Antonio
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- NEXT Oncology San Antonio, San Antonio
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Nagre-recruitPhase 2
- Texas Oncology- San Antonio, San Antonio
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Nagre-recruitPhase 1/2
- Research Site, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Nagre-recruitPhase 1/2
- START San Antonio, San Antonio
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #3, San Antonio
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Nagre-recruitObservasyonal na pag-aaral
- Texas Oncology, PA - Metropolitan, San Antonio
- Texas Oncology, PA - Northeast, San Antonio
- UT Health Cancer Center, San Antonio
- at 2 pa
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 2
- Texas Oncology PA (San Antonio), San Antonio
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Nagre-recruitPhase 1
- Biotheryx Investigative Site, San Antonio
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa San Antonio
- Non-Small Cell Lung Cancer59 pag-aaral
- Colorectal Cancer46 pag-aaral
- Metastatic Cancer44 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Obesity40 pag-aaral
- Type 2 Diabetes37 pag-aaral
- Overweight34 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Kanser sa Pancreas31 pag-aaral
- Kanser sa Prostate28 pag-aaral
- Kanser ng Endometrium27 pag-aaral
- Kanser sa Baga26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.